Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Intensity Therapeutics (NASDAQ:INTS) and maintained a $12 price target.
August 24, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intensity Therapeutics has been reiterated as a Speculative Buy by Benchmark with a maintained price target of $12.
The reiteration of a Speculative Buy rating by Benchmark indicates a positive outlook for Intensity Therapeutics. The maintained price target of $12 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100